Using an inhibitor of GCLC, buthionine sulfoximine (BSO), we found that BSO treatment significantly decreased intracellular GSH level, increased Erastin-induced cell death and inhibited proliferation in tumor cells co-cultured with CBS-disrupted CAFs (Figure S6A-C). Here, GCLC is linked to neoplasm.